NASDAQ:TBPH Theravance Biopharma (TBPH) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free TBPH Stock Alerts $9.14 -0.03 (-0.33%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$9.00▼$9.3350-Day Range$8.52▼$9.9252-Week Range$8.21▼$11.98Volume387,247 shsAverage Volume403,964 shsMarket Capitalization$443.84 millionP/E RatioN/ADividend YieldN/APrice Target$20.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Theravance Biopharma alerts: Email Address Theravance Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.3% Upside$20.50 Price TargetShort InterestBearish14.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$10,922 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.84) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector541st out of 908 stocksPharmaceutical Preparations Industry240th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingTheravance Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTheravance Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.72% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently decreased by 14.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TBPH. Previous Next 1.2 News and Social Media Coverage News SentimentTheravance Biopharma has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Theravance Biopharma this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Theravance Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,922.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Theravance Biopharma is held by insiders.Percentage Held by Institutions99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Theravance Biopharma are expected to grow in the coming year, from ($0.84) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is -9.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is -9.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheravance Biopharma has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Theravance Biopharma Stock (NASDAQ:TBPH)Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Read More TBPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TBPH Stock News HeadlinesApril 18, 2024 | americanbankingnews.comTheravance Biopharma, Inc. Expected to Earn FY2024 Earnings of ($0.89) Per Share (NASDAQ:TBPH)April 17, 2024 | msn.comTheravance Biopharma (TBPH) Price Target Increased by 10.00% to 15.71April 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 17, 2024 | americanbankingnews.comQ1 2026 Earnings Estimate for Theravance Biopharma, Inc. (NASDAQ:TBPH) Issued By Zacks ResearchApril 15, 2024 | investorplace.comBTIG Research Predicts Over 118% Rally for These 3 StocksApril 10, 2024 | finance.yahoo.comTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024April 10, 2024 | prnewswire.comTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024March 12, 2024 | investorplace.comShort-Squeeze Showdown: 3 Stocks Ready to Crush the SkepticsApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 7, 2024 | markets.businessinsider.comAnalyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment PotentialFebruary 28, 2024 | markets.businessinsider.comTheravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic MilestonesFebruary 28, 2024 | finance.yahoo.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | stockhouse.comTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 27, 2024 | investing.comTheravance Biopharma Inc (TBPH)February 27, 2024 | markets.businessinsider.comBalancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance BiopharmaFebruary 26, 2024 | msn.comTheravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03MFebruary 26, 2024 | prnewswire.comTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 25, 2024 | seekingalpha.comTheravance Biopharma Q4 2023 Earnings PreviewFebruary 24, 2024 | benzinga.comTheravance Biopharma Stock (NASDAQ:TBPH) Dividends: History, Yield and DatesFebruary 24, 2024 | msn.comTheravance Biopharma (TBPH) Price Target Increased by 5.77% to 14.03February 22, 2024 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceFebruary 15, 2024 | finance.yahoo.comWill Theravance Biopharma (NASDAQ:TBPH) Spend Its Cash Wisely?February 14, 2024 | finance.yahoo.comTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024February 14, 2024 | prnewswire.comTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024February 1, 2024 | finance.yahoo.comTheravance Biopharma, Inc. (TBPH)January 19, 2024 | finance.yahoo.comAnalysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before LongJanuary 12, 2024 | finance.yahoo.comDown -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a TurnaroundSee More Headlines Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/26/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees359Year FoundedN/APrice Target and Rating Average Stock Price Target$20.50 High Stock Price Target$21.00 Low Stock Price Target$20.00 Potential Upside/Downside+124.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,190,000.00 Net Margins-96.12% Pretax Margin-85.80% Return on Equity-19.31% Return on Assets-12.03% Debt Debt-to-Equity RatioN/A Current Ratio5.39 Quick Ratio5.39 Sales & Book Value Annual Sales$57.42 million Price / Sales7.73 Cash FlowN/A Price / Cash FlowN/A Book Value$4.28 per share Price / Book2.14Miscellaneous Outstanding Shares48,560,000Free Float45,209,000Market Cap$443.84 million OptionableOptionable Beta0.36 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesRick E. WinninghamChairman & Chief Executive OfficerAndrew Asa HindmanChief Financial Officer & Senior Vice PresidentVijay SabesanSenior Vice President-Technical OperationsPhilip D. WorboysSenior VP-Research & Translational ScienceBradford J. ShaferSecretary, Executive VP & General CounselKey CompetitorsShattuck LabsNASDAQ:STTKAcelyrinNASDAQ:SLRNIGM BiosciencesNASDAQ:IGMSTravere TherapeuticsNASDAQ:TVTXAdlai NortyeNASDAQ:ANLView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 40,166 shares on 4/24/2024Ownership: 0.083%Wellington Management Group LLPBought 116,164 shares on 3/5/2024Ownership: 0.577%Gerber LLCBought 10,000 shares on 3/5/2024Ownership: 0.020%Rhonda FarnumSold 1,254 sharesTotal: $10,922.34 ($8.71/share)Park West Asset Management LLCSold 1,083,251 shares on 2/15/2024Ownership: 1.807%View All Insider TransactionsView All Institutional Transactions TBPH Stock Analysis - Frequently Asked Questions Should I buy or sell Theravance Biopharma stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TBPH shares. View TBPH analyst ratings or view top-rated stocks. What is Theravance Biopharma's stock price target for 2024? 2 equities research analysts have issued 12-month target prices for Theravance Biopharma's shares. Their TBPH share price targets range from $20.00 to $21.00. On average, they expect the company's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 124.3% from the stock's current price. View analysts price targets for TBPH or view top-rated stocks among Wall Street analysts. How have TBPH shares performed in 2024? Theravance Biopharma's stock was trading at $11.24 at the beginning of 2024. Since then, TBPH shares have decreased by 18.7% and is now trading at $9.14. View the best growth stocks for 2024 here. Are investors shorting Theravance Biopharma? Theravance Biopharma saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 6,430,000 shares, a decline of 14.5% from the March 31st total of 7,520,000 shares. Based on an average trading volume of 367,200 shares, the short-interest ratio is currently 17.5 days. Currently, 14.7% of the company's shares are sold short. View Theravance Biopharma's Short Interest. When is Theravance Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our TBPH earnings forecast. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) issued its earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.02. The biopharmaceutical company had revenue of $17.57 million for the quarter, compared to analyst estimates of $17.49 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 19.31% and a negative net margin of 96.12%. What ETFs hold Theravance Biopharma's stock? ETFs with the largest weight of Theravance Biopharma (NASDAQ:TBPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX). Who are Theravance Biopharma's major shareholders? Theravance Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.08%). Insiders that own company stock include Rhonda Farnum, Richard A Graham and Rick E Winningham. View institutional ownership trends. How do I buy shares of Theravance Biopharma? Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TBPH) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
